Scott Harlan Maw
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Chipotle Shares Dip Amid Near‑Term Sales Pressure, UBS Projects 2027 Growth. Chipotle shares fell more than the broader market today as analysts noted near‑term sales pressure. UBS still projects stronger growth in 2027, citing a recovery in sales growth. The chain’s strategy shift—expanding menu and store size—mirrors KFC’s recent move to smaller formats. With the stock trading near its 13‑touch support level of $32.02 and an RSI of 40.1, the market is watching for a possible rebound.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Avista (AVA) Faces Barclays downgrade and upcoming earnings call. Barclays kept an equal‑weight rating on Avista but cut its price target to $35, indicating a more cautious view. The company announced the date for its third‑quarter 2026 earnings conference call, which may provide further insight into performance. A recent Yahoo analysis highlighted the stock’s potential upside relative to its risk profile, noting its dividend yield and valuation. These items come as the stock trades near its recent support level.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Wells Fargo cuts Root price target to $47. Wells Fargo lowered its price target for Root to $47 while maintaining an Equal-Weight rating. This adjustment occurs as the stock trades near its 52-week low, with the new target sitting below the current average analyst estimate of $57. The move reflects a more cautious outlook for the insurer amidst broader industry developments.
Transaction History
| BROS | ▲ Buy | Option Exercise | 775 | $0 | 8/20/2026 | View on chart |
| CMG | ▲ Buy | Grant | 6,880 | $215K | 6/11/2026 | View on chart |
| AVA | ▲ Buy | Grant | 3,538 | $145K | 5/8/2026 | View on chart |
| AVA | ▲ Buy | Grant | 91 | $3K | 9/2/2025 | View on chart |
| CMG | ▲ Buy | Grant | 4,152 | $215K | 6/11/2025 | View on chart |
| AVA | ▲ Buy | Grant | 3,232 | $135K | 5/5/2025 | View on chart |
| CMG | ▼ Sell | Gift | 1,580 | $0 | 2/10/2025 | View on chart |
| AVA | ▲ Buy | Grant | 43 | $2K | 9/3/2024 | View on chart |
| CMG | ▲ Buy | Grant | 67 | $0 | 6/6/2024 | View on chart |
| AVA | ▲ Buy | Grant | 3,533 | $130K | 5/3/2024 | View on chart |
| AVA | ▲ Buy | Grant | 50 | $2K | 9/1/2023 | View on chart |
| CMG | ▲ Buy | Grant | 105 | $0 | 5/25/2023 | View on chart |
| AVA | ▲ Buy | Grant | 2,839 | $125K | 5/15/2023 | View on chart |
| ROOT | ▲ Buy | Grant | 1,255 | $8K | 12/30/2022 | View on chart |
| ROOT | ▲ Buy | Grant | 631 | $8K | 9/30/2022 | View on chart |
| AVA | ▲ Buy | Grant | 123 | $5K | 9/1/2022 | View on chart |
| ROOT | ▲ Buy | Grant | 6,308 | $8K | 6/30/2022 | View on chart |
| ROOT | ▲ Buy | Grant | 115,207 | $0 | 6/7/2022 | View on chart |
| CMG | ▲ Buy | Grant | 140 | $0 | 5/19/2022 | View on chart |
| AVA | ▲ Buy | Grant | 2,564 | $110K | 5/16/2022 | View on chart |
| ROOT | ▲ Buy | Grant | 4,826 | $8K | 3/31/2022 | View on chart |
| AVA | ▲ Buy | Grant | 159 | $7K | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Dutch Bros shares near 52-week low amid mixed analyst views
Dutch Bros stock has fallen 21% in September, bringing it close to its 52-week low. While the company is exploring new walk-up locations, analysts like Baird and DA Davidson have recently lowered their price targets, though they still see potential upside. The stock currently trades well below the average analyst target of $72.92.
Dutch Bros shares near 52-week low amid mixed analyst views. Dutch Bros stock has fallen 21% in September, bringing it close to its 52-week low. While the company is exploring new walk-up locations, analysts like Baird and DA Davidson have recently lowered their price targets, though they still see potential upside. The stock currently trades well below the average analyst target of $72.92.